NASDAQ:ORKA Oruka Therapeutics Q1 2025 Earnings Report $9.71 +0.09 (+0.94%) As of 05/14/2025 04:00 PM Eastern Earnings HistoryForecast Oruka Therapeutics EPS ResultsActual EPS-$0.40Consensus EPS -$0.57Beat/MissBeat by +$0.17One Year Ago EPSN/AOruka Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOruka Therapeutics Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateWednesday, May 21, 2025Conference Call Time12:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Oruka Therapeutics Earnings HeadlinesOruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14 at 4:15 PM | globenewswire.comTrinity Biotech (NASDAQ:TRIB) vs. Oruka Therapeutics (NASDAQ:ORKA) Critical ContrastMay 5, 2025 | americanbankingnews.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 15, 2025 | Golden Portfolio (Ad)Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care ConferenceApril 29, 2025 | globenewswire.comWe're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn RateMarch 8, 2025 | finance.yahoo.comOruka Therapeutics at Risk: Navigating Licensing Challenges and Partner RelianceMarch 8, 2025 | tipranks.comSee More Oruka Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email. Email Address About Oruka TherapeuticsOruka Therapeutics (NASDAQ:ORKA) is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.View Oruka Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery? Upcoming Earnings NetEase (5/15/2025)Applied Materials (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Palo Alto Networks (5/19/2025)PDD (5/20/2025)Synopsys (5/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
